Skip to main content
. 2021 Sep 8;111(4):428–439. doi: 10.1007/s00392-021-01913-z

Fig. 3.

Fig. 3

Graphical ranking of SGLT2i based on SUCRA values (hospitalization for HF or CV death). CANA canagliflozin, CV cardiovascular, DAPA dapagliflozin, EMPA empagliflozin, ERTU ertugliflozin, HF heart failure, PLA placebo, SITA sitagliptin, SOTA sotagliflozin